汤森路透2015全球新药光荣榜

2016-01-06 佚名汤森路透

汤森路透数据显示，2015年(截至2015年12月15日，下同)，全球共有49个新分子实体(NME)和生物药首次获批并推向市场。另外，全球范围内，已上市药物里有29个重要的产品线延伸首次获得批准，包括新适应症、新剂型或者新复方；21个新分子实体在全球首次获批，但还未上市。虽然这些数字表明制药和生物技术行业整体上运行良好，但与去年全球59个上市新药相比，数量明显下降。不过，质量远比数量重要，20

汤森路透数据显示，2015年(截至2015年12月15日，下同)，全球共有49个新分子实体(NME)和生物药首次获批并推向市场。另外，全球范围内，已上市药物里有29个重要的产品线延伸首次获得批准，包括新适应症、新剂型或者新复方；21个新分子实体在全球首次获批，但还未上市。

虽然这些数字表明制药和生物技术行业整体上运行良好，但与去年全球59个上市新药相比，数量明显下降。不过，质量远比数量重要，2015年上市新药中有一些非常杰出的成员。

癌症新药十年来最多

对于癌症患者来说，今年非常值得庆贺，因为2015年是近十年来上市新癌症药数量最多的一年。总体来说，全球范围内共有14个新的癌症药物首次推向市场。

其中，多发性骨髓瘤是个最明显的领域。2015年，有4个多发性骨髓瘤新药获批并上市。在此之前，已有十年没有多发性骨髓瘤新药上市了，市场上仅有屈指可数的几个治疗药物。借用多发性骨髓瘤研究基金会主席Walter Capone的话说，2015年，对于美国9万这种罕见血液癌症患者来说，是个“分水岭”。

首个疾病治疗/预防新药

一些无药可治的疾病在2015年有新药上市，其中一部分用于常见病，另一些则用于极为罕见的疾病。

Shire的Vyvanse(甲磺酸赖氨酸安非他命)是首个用于成人中度至重度暴食症(BED)的药物。估计在美国有280万成人患有暴食症，是最常见的饮食失调疾病。

Addyi(氟班色林)是首个治疗女性性欲减退疾病的药物。在两次拒绝NDA后，2015年FDA最终批准了这个产品。不过因为潜在的严重副作用，在使用上加以严格限制。这个药物的批准引发争议，最近FDA在《新英格兰医学杂志》上阐述了该机构作出批准决定的原因。

罕见出血性疾病遗传性凝血因子X缺陷症在美国仅有400～600名患者，对于这些患者来说，2015年将是值得铭记的一年，用于这一疾病的治疗药物——BPL公司的Coagadex(人源化凝血因子X)终于面世。

此外，用于极罕见致命疾病低磷酸酯酶症的首个治疗药物——Alexion的asfotase alfa(Strensiq)在一些国家获得批准并上市。

另一个有史以来的第一次是，赛诺菲巴斯德的四价登革热疫苗于12月中旬在墨西哥首次获得批准。为了开发这个疫苗，赛诺菲花了20年时间。墨西哥监管机构批准了这个名为Dengvaxia的疫苗，用于疾病流行地区的少年、青少年和成年人预防全部4重血清型的登革热病毒感染。Denvaxia将在2016年上市。

新一批First-in-Class

2015年，有11个作用机制为首创的创新药推向市场，其中包括2个用于高胆固醇血症的创新药。大约十年前，对于那些对标准治疗他汀无效的患者，抑制循环蛋白前蛋白转化酶枯草杆菌蛋白酶Kevin9型(PCSK9)被认为是一个有前途的降低低密度脂蛋白(LDL)胆固醇的新策略。PCSK9通过促进LDL受体降解造成高胆固醇血症。2015年夏天，在开发PCSK9抑制剂的赛跑中，2个抗PCSK9单抗几乎同时获得批准，分别是evolocumab(Repatha，安进)和alirocumab(Praluent，Regeneron/赛诺菲)。

2015年上市的其他首创新药包括：抗IL-5单抗mepolizumab(Nucala；葛兰素史克)，已上市用于哮喘；抗IL-17A单抗secukinumab(Cosentyx；诺华)，已上市用于银屑病和银屑病关节炎，已批准用于强制性脊柱炎；抗SLAMF7单抗elotuzumab(Empliciti；艾伯维/百时美施贵宝)，已上市用于多发性骨髓瘤；细胞周期蛋白依赖性激酶(CDK)4/6抑制剂palbociclib(Ibrance；辉瑞)，已上市用于乳腺癌。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (10)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-13 medsic

哦，

159 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-13 medsic

哦，

153 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-13 medsic

了解，

197 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-13 medsic

了解，

133 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-13 medsic

感谢分享～～

139 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-13 medsic

感谢分享～～

82 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-08 1249894fm77暂无昵称

#汤森路透#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-06 wzf990214

牛

150 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-06 wzf990214

赞

77 0
[GetPortalCommentsPageByObjectIdResponse(id=56613, encodeId=59ee56613ba, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56614, encodeId=ce8e5661453, content=哦，, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56615, encodeId=daad5661595, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56616, encodeId=296556616f7, content=了解，, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56617, encodeId=8d3d5661e2b, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56618, encodeId=b70a56618a1, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:40:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544339, encodeId=7049154433919, content=<a href='/topic/show?id=a29a6438e5c' target=_blank style='color:#2F92EE;'>#汤森路透#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64387, encryptionId=a29a6438e5c, topicName=汤森路透)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=387e13658673, createdName=1249894fm77暂无昵称, createdTime=Fri Jan 08 01:19:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52530, encodeId=de2f5253002, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52531, encodeId=1c8152531f0, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Wed Jan 06 20:24:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52447, encodeId=739d5244e93, content=抗癌药物比较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Wed Jan 06 17:22:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
2016-01-06 鲜花飞鸟

抗癌药物比较好

62 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

汤森路透2015全球新药光荣榜

相关资讯

科室

工具

服务